Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CAPNS1 | P04632 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598052 | 0.99 | NR1H4 (0.51) | NR1H4MEN1KMT2AELANECAPNS1 | |
| SCHEMBL3838373 | 0.96 | NR1H4 (0.50) | NR1H4MEN1KMT2AELANECAPNS1 | |
| SCHEMBL5706924 | 0.95 | NR1H4 (0.56) | NR1H4MEN1KMT2AELANEKDM4E | |
| SCHEMBL6989461 | 0.94 | NR1H4 (0.51) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL3831703 | 0.92 | NR1H4 (0.51) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL4619436 | 0.92 | NR1H4 (0.50) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL4598195 | 0.92 | NR1H4 (0.50) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL4618555 | 0.91 | NR1H4 (0.46) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL5706907 | 0.91 | NR1H4 (0.49) | NR1H4ELANECAPNS1CAPN1CTSD | |
| SCHEMBL14677996 | 0.91 | NR1H4 (0.48) | NR1H4MEN1KMT2AELANECAPNS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | claimed |
| EP-2013165-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | Astra Zeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007126358-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1641749-A1 | POTASSIUM OR SODIUM SALT OF (-)-2- {'2-(4-HYDROXYPHENYL)ETHYL]-THIO -3-'4-(2- {4-'(METHYLSULFONYL)OXY ]PHENOXY }PHENYL]PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638930-A1 | AMINE SALTS OF (-)-2- ¬2-(4-HYDROXYPHENYL)ETHYL|-THIO -3-¬4-(2- 4-¬(METHYLSULFONYL)OXY|PHENOXY ETHYL)PHENYL|PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638922-A1 | PHARMACEUTICALLY USEFUL SALTS OF CARBOXYLIC ACID DERIVATES | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638921-A1 | PHARMACEUTICALLY USEFUL SALTS OF CARBOXYLIC ACID DERIVATES | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638926-A1 | 2-ETHOXY-3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF LIPID DISORDERS | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1610770-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004113283-A1 | AMINE SALTS OF (-)-2-{`2-(4-HYDROXYPHENYL) ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY! PHENOXY}ETHYL)PHENYL! PROPANOIC ACID AND THERE USE IN MEDICINE | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113276-A1 | 2-ETHOXY-3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF LIPID DISORDERS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004110985-A1 | PHARMACEUTICALLY USEFUL SALTS OF CARBOXYLIC ACID DERIVATES | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110984-A1 | PHARMACEUTICALLY USEFUL SALTS OF CARBOXYLIC ACID DERIVATES | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| EP-1478368-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | Astrazeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004089350-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003061663-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | WO | disclosed |